Back to search

Article

Molnupiravir as a Safer Alternative to Nirmatrelvir/Ritonavir in Kidney and Pancreas-Kidney Transplant Recipients Receiving Tacrolimus: A Single-Center Retrospective Analysis

2026-08-05

Abstract excerpt

<h4>Background: </h4> Calcineurin inhibitor (CNI)-based immunosuppression after solid organ transplantation increases the risk of severe COVID-19. Nirmatrelvir/ritonavir, the guideline-preferred oral antiviral in the general population, causes a well-documented, potentially dangerous drug-drug interaction (DDI) with tacrolimus via ritonavir-mediated inhibition of cytochrome P450 3A4 (CYP3A4). Molnupiravir lacks th...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
f3f84b21-68df-5ee8-9dcc-ba26967988e3
DOI
10.20944/preprints202608.0297.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Molnupiravir as a Safer Alternative to Nirmatrelvir/Ritonavir in Kidney and Pancreas-Kidney Transplant Recipients Receiving Tacrolimus: A Single-Center Retrospective AnalysisDOI 10.20944/preprints202608.0297.v1
Pharmacokinetics of nirmatrelvir/ritonavir and the drug-drug interaction with calcineurin inhibitor in renal transplant recipients.Semantic proximity
Successful Management of Severe COVID-19 in a Kidney Transplant Recipient Safe Co-Administered Tacrolimus and Ensitrelvir: A Case ReportSemantic proximity
Direct-acting antiviral therapy for hepatitis C virus infection in the kidney transplant recipient.Semantic proximity
Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir Regimen in the Treatment of Genotype 1 Chronic Hepatitis C Infection in Patients with Severe Renal Impairment and End-Stage Renal Disease: a Real-Life Cohort.Semantic proximity
Risk of acute renal failure associated with combined use of SGLT2 inhibitors and potentially nephrotoxic drugs: a pharmacovigilance study based on the FAERS databaseSemantic proximity
Utilization of an EMR-biorepository to identify the genetic predictors of calcineurin-inhibitor toxicity in heart transplant recipients.Semantic proximity
Pharmacogenomics-based tacrolimus combined with Wuzhi capsules in precision medicine in kidney transplant patientsSemantic proximity
Ombitasvir-Paritaprevir-Ritonavir Therapy in a Kidney Transplant Recipient With Chronic Hepatitis C Virus Genotype 1 Infection: A Case Report on the Importance of Considering Drug-Drug Interactions and Monitoring Cyclosporine Levels.Semantic proximity
Efficacy of ombitasvir/paritaprevir/ritonavir/ribavirin in management of HCV genotype 4 and end-stage kidney disease.Semantic proximity
Clinical Outcomes of Post Renal Transplant Patients with COVID-19 Infection: A single-center case seriesSemantic proximity
Predictors of tacrolimus dose optimization when drug-drug interaction associated with voriconazole in heart transplant recipientsSemantic proximity
Understanding and Preventing Adverse Effects of Tacrolimus Metabolization in Transplant Patients.Semantic proximity
Select a neighboring publication to make it the new centre.